<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083052</url>
  </required_header>
  <id_info>
    <org_study_id>UFPa - 0011</org_study_id>
    <nct_id>NCT05083052</nct_id>
  </id_info>
  <brief_title>Propolis in Reducing Dentin Hypersensitivity</brief_title>
  <official_title>Propolis in Reducing Dentin Hypersensitivity: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Para</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Para</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: This randomized, double-blind, parallel, placebo-controlled clinical trial aims to&#xD;
      evaluate the effect of propolis with two distinct concentrations (10% and 15%), and the&#xD;
      impact on volunteers' quality of life.&#xD;
&#xD;
      Materials and methods: Volunteers meeting the inclusion and exclusion criteria will be&#xD;
      randomized and allocated into three groups: Group 1- placebo - toothpaste without active&#xD;
      ingredient, Group 2- toothpaste with 10% propolis and Group 3. - toothpaste with 15%&#xD;
      propolis. Number of teeth will be used as sample unit, totaling 22 teeth per group.&#xD;
      Volunteers will receive oral hygiene instruction with guidance to brush their teeth three&#xD;
      times a day with toothpaste corresponding to the groups in which they will be allocated for&#xD;
      30 days. The evaluation of dentin hypersensitivity will be performed with three (3)&#xD;
      evaluation times: baseline (immediately before the beginning of treatment), 15 and 30 days,&#xD;
      through tactile and evaporative stimuli, using the visual analog scale (VAS). The&#xD;
      self-reported evaluation of the volunteers will be done through a questionnaire before the&#xD;
      beginning and after one month with the completion of the research to determine the impact of&#xD;
      treatment on their quality of life. The data regarding HD in VAS, if present normal&#xD;
      distribution, will be used Two-way analysis of variance (ANOVA) with Tukey's post hoc for&#xD;
      comparison between treatments. However, if the data show anormal distribution, Friedman to&#xD;
      compare the different times in the same group (intra group), and Kruskal Wallis to make the&#xD;
      comparison between groups (inter group). To evaluate the QEHD ordinal data, Wilcoxon and&#xD;
      Mann-Whitney tests will be used. Bioestat 5.3 (Belém, Pará, Brazil) will be used, considering&#xD;
      an alpha level of 5%.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dentin hypersensitivity</measure>
    <time_frame>30 days</time_frame>
    <description>The evaluation of dentin hypersensitivity will be performed with three (3) evaluation times: baseline (immediately before the beginning of treatment), 15 and 30 days, through tactile and evaporative stimuli, using the visual analog scale (VAS) from 0 to 10, where 0 represents no pain and 10 extreme pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>30 days</time_frame>
    <description>The self-reported evaluation of the volunteers will be completed through a questionnaire before the beginning and after one month with the completion of the research to determine the impact of treatment on their quality of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Dentin Sensitivity</condition>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Carbonato de cálcio: 40,0%, Glicerina: 20,0%, Lauril Sulfato de sódio: 1,2%, Carboximetilcelulose: 2,0%, Goma xantana: 1,0%, Metilparabeno (nipagim): 0,15%, EDTA: 0,5%, Sacarina: 0,1%, Flavorizante: 0,75%, Água deionizada q.s.p - 100mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOLIS 10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carbonato de cálcio: 40,0%, Glicerina: 20,0%, Lauril Sulfato de sódio: 1,2%, Carboximetilcelulose: 2,0%, Goma xantana: 1,0%, Metilparabeno (nipagim): 0,15%, EDTA: 0,5%, Sacarina: 0,1%, Flavorizante: 0,75%, Própolis a 10%, Água deionizada q.s.p - 100mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOLIS 15%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carbonato de cálcio: 40,0%, Glicerina: 20,0%, Lauril Sulfato de sódio: 1,2%, Carboximetilcelulose: 2,0%, Goma xantana: 1,0%, Metilparabeno (nipagim): 0,15%, EDTA: 0,5%, Sacarina: 0,1%, Flavorizante: 0,75%, Própolis a 15%, Água deionizada q.s.p - 100mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Propolis 15%</intervention_name>
    <description>oothpaste formulation with 15% propolis.</description>
    <arm_group_label>PROPOLIS 15%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Propolis 10%</intervention_name>
    <description>Toothpaste formulation with 10% propolis.</description>
    <arm_group_label>PROPOLIS 10%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Formulation of toothpaste without active ingredient.</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Two to four hypersensitive teeth with a response ≥ 04 on the visual analogue scale&#xD;
             (VAS) from 0 to 10, where 0 represents no pain and 10 extreme pain, during the&#xD;
             application of tactile (explorer probe) and evaporative (jet air);&#xD;
&#xD;
          -  Dentinal exposure on the posterior teeth, due to the presence of a shallow non-carious&#xD;
             lesion up to 02 mm in depth, according to the Smith &amp; Knight index (measured with a&#xD;
             millimeter probe), and / or class I gingival recession according to Miller&#xD;
             classification.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Restorations; tooth decay and/or periodontal pockets; dental pulpitis; enamel cracks&#xD;
             or fractures on sensitive teeth;&#xD;
&#xD;
          -  Continuous treatment with anti-inflammatory drugs and/or analgesics or desensitizing&#xD;
             treatment induced three months prior to research recruitment data;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Systemic diseases;&#xD;
&#xD;
          -  Fixed orthodontic appliances;&#xD;
&#xD;
          -  Occlusal instability.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cecy M Silva, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Pará</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidade Federal do Pará</name>
      <address>
        <city>Belém</city>
        <state>PA</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Para</investigator_affiliation>
    <investigator_full_name>Cecy Martins Silva</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>Dentin Desensitizing Agents; Propolis.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dentin Sensitivity</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propolis</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

